✦ LIBER ✦

Long-Term Efficacy and Tolerability of 20% Scig in the Treatment of Patients with Primary Immunodeficiency Disease

✍ Scribed by Borte, Michael; Wasserman, Richard L.; Rojavin, Mikhail; Bexon, Martin; Jolles, Stephen

Book ID: 123458570
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 40 KB
Volume: 131
Category: Article
ISSN: 1097-6825
DOI: 10.1016/j.jaci.2012.12.1219

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term efficacy, safety, and tolerabi

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

✍ Jolles, Stephen; Borte, Michael; Nelson, Robert P.; Rojavin, Mikhail; Bexon, Mar 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Efficacy and Tolerability of an Argentin

Efficacy and Tolerability of an Argentine Intravenous Immunoglobulin in Pediatric Patients with Primary Immunodeficiency Diseases

✍ S. Krasovec; A. Ornani; M. Oleastro; S. Rosenzweig; A. Roy; L. Perez; G. Campos; 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 175 KB

The efficacy and tolerability of long-te

The efficacy and tolerability of long-term felodipine treatment in hypertension

✍ H. Borgmästars; B. Forsén; J. Tuomilehto; R. Hellebø; P. O. Walle; H. M. Nielsen 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 612 KB

Long-Term Efficacy and Tolerability of A

Long-Term Efficacy and Tolerability of Acarbose Treatment in Patients with Type 2 Diabetes Mellitus

✍ Dr Pesach Segal, Haskel E. Eliahou, Dieter Petzinna, Dieter Neuser, Andreas Brüc 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 99 KB

The long-term efficacy and tolerability

The long-term efficacy and tolerability of donepezil in patients with vascular dementia

✍ David Wilkinson; Gustavo Róman; Stephen Salloway; Jane Hecker; Karyn Boundy; Din 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 2 views

## Abstract ## Objective To determine the long‐term tolerability and efficacy of donepezil in patients with vascular dementia (VaD). ## Methods International, multicentre, open‐label, 30‐week extension study of two 24‐week, randomised, double‐blind, placebo‐controlled studies. Participants were

Efficacy and Safety of IgPro20, a Subcut

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases

✍ Kanegane, Hirokazu; Imai, Kohsuke; Yamada, Masafumi; Takada, Hidetoshi; Ariga, T 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 212 KB